
The Effects of a Modified-Risk Claim for an ENDS Product to Increase Smokers' Behavioral Intentions to Use the Product Are Completely Mediated by the Claim's Effects on Risk Perceptions

Saul Shiffman, Ph.D.
Senior Scientific Advisor, Pinney Associates
Consulting to JUUL Labs

Stacey McCaffrey, Ph.D. Ryan Black, Ph.D. JUUL labs, Inc.

Why Do We Care About Risk Perceptions?

- Because facts matter
- Because they influence behavior
- Health-behavior models posit causal link between risk perceptions and behavior
- The Modified-Risk provisions in the Tobacco Control Act implicitly assume that link




Modified Risk Tobacco Product Application (MRTPA) Provisions


- The Tobacco Control Act allows manufacturers to communicate to consumers regarding reduced disease risk [Sec 911g(1)] or reduced exposure to toxicants [Sec 911g(2)], subject to FDA review and authorization (APPH standard)
- For MRTPA, FDA asks applicants to provide data on the effect of the proposed claim on:
 - Behavioral intentions
 - Risk perceptions

Proposed Reduced Exposure Claim (g2) for JUUL 5% nicotine US product






Claims Testing Overview: Randomized Test



The Claims Testing Relative Risk Rating Task: Indirect Assessment of Relative-Risk Perceptions

- Respondents shown multiple target behaviors (inc. cigarettes and JUUL), in randomized order
- Choose most harmful and least harmful
- Shown list, least harmful at top, most harmful at bottom, rest randomized
- Rate each on 0%-100% scale







TSRC2023(76) - Document not peer-reviewed by CORESTA


RELATIVE RISK RATINGS

Control





Exposure to the message decreased perceived risk of using JUUL



JUUL*

*Significant difference

100

MORE HARMFUL

90

Exposure to the message increased perceived risk of cigarette smoking

80

70


60

50

LESS HARMFUL

RELATIVE RISK RATINGS


● Control ▲ Message



Exposure to the message increased perceived risk *differential* between cigarette smoking and using JUUL


"Openness to Use" = Absence of Complete Rejection of Use

- 4-item Intention to Use assessment
- e.g., "I would consider using a JUUL e-cigarette more than once"
- Strongly disagree
- Disagree
- Somewhat disagree
- Somewhat agree
- o Agree
- Strongly agree
- "Not Open" = Strongly disagree to all items
- "Open" = any response other than Strongly disagree to even a single item
- Very low-threshold criterion




Effects of the Message Exposure


- 4-item Openness to Use assessment
- e.g., I would consider using a JUUL e-cigarette more than once
- Strongly disagree
- Disagree
- Somewhat disagree
- Somewhat agree
- o Agree
- "Not Open" = Strongly disagree to all items
- "Open" = any response other than Strongly disagree to even a single item
- Very low-threshold criterion



What Role Does Change in Risk Perceptions Play in Change in Behavioral Intentions?



What Role Does Change in Risk Perceptions Play in Change in Behavioral Intentions?




Perceived Risk Reduction completely accounts for the impact of the claim on Openness

Conclusions

- As posited by theory and assumed by the TCA
- Reduced-exposure (reduced-risk?) communications affect behavioral use intentions by affecting risk perceptions
- Consistent with observational data that risk perceptions predict use (and switching away from cigarette smoking)

Headed in the Wrong Direction: Misperceptions of Relative Risk of ENDS Increasing



Correcting Misperceptions of Noncombustible Tobacco Products

"Opportunities exist to educate adult smokers about the relative risks of tobacco products, including e-cigarettes...

FDA recently initiated formative research to inform potential messaging related to misperceptions about nicotine and the continuum of risk among adult smokers."

King, BA*, Toll, BA. Commentary on Wackowski et al.: Opportunities and Considerations for Addressing Misperceptions About the Relative Risks of Tobacco Products among Adult Smokers. Addiction. 2023. https://doi.org/10.1111/add.16296

*Director of the FDA's Center for Tobacco Products